{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF01413",
      "entity_text" : "C4",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5462224",
      "entity_text" : "mg",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Consistent with findings in C4, 300 mg weekly dupilumab significantly reduced the proportion of days TCS and systemic rescue medications were used by participants over 16 weeks compared to placebo (28.9 vs 18.5%; P < 0.0001) and 52 weeks (33.7 vs 23.7%; P < 0.0001).",
  "reading_complete" : "2020-08-05T22:34:06Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:32:35Z",
  "trigger" : "reduced",
  "evidence" : [ "C4, 300 mg weekly dupilumab significantly reduced" ],
  "pmc_id" : "5826246",
  "score" : 0
}